We're a private, clinical-stage biopharmaceutical company committed to developing a best-in-class, novel therapy for hypertension.
Location: Canada
Total raised: $470M
Investors 6
| Date | Name | Website |
| 03.07.2022 | Ysios Capi... | ysioscapit... |
| - | Andera Par... | anderapart... |
| - | Adams Stre... | adamsstree... |
| - | HBM Partne... | hbmpartner... |
| 17.04.2021 | Catalys Pa... | catalyspac... |
| 14.06.2022 | SR One | srone.com |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 08.02.2024 | - | $120M | - |
| 14.02.2023 | IPO | $192M | - |
| 09.06.2022 | Series B | $118M | Andera Par... |
| 07.04.2021 | Series A | $40M | - |
Mentions in press and media 15
| Date | Title | Description |
| 03.05.2025 | Unraveling the Mysteries of Blood Pressure and Consciousness | In the world of medicine, two recent studies shine a light on pressing health issues: blood pressure management and the enigma of consciousness. Both topics, while seemingly disparate, share a common thread: the quest for understanding and ... |
| 29.04.2025 | Blood pressure-lowering medication shows promise in new trial results | Being able to reduce pressure by 15 points, he said, could be clinically significant, especially for those on the more extreme side of the scale. “We would expect that being able to help these patients achieve safer blood pressure levels wi... |
| 08.02.2024 | Mineralys Therapeutics Announces $120 Million Private Placement Financing | RADNOR, Pa., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (“CKD”) and other diseases... |
| 08.02.2024 | Mineralys Therapeutics Announces $120 Million Private Placement Financing | - |
| 14.02.2023 | Ysios Capital anuncia la salida a bolsa en el NASDAQ de su participada Mineralys Therapeutics | 14/02/2023 Nota de prensa YSIOS CAPITAL ANUNCIA LA SALIDA A BOLSA EN EL NASDAQ DE SU PARTICIPADA MINERALYS THERAPEUTICS Ysios Capital, gestora española líder en inversiones en el sector biotecnológico, ha anunciado hoy la salida a bolsa ... |
| 14.02.2023 | Mineralys Therapeutics Completes $192M IPO | Mineralys Therapeutics, a US-based clinical-stage biopharmaceutical company, completed last Friday a $192m initial public offering (IPO) on the Nasdaq Global Select Market at $16.00 per share. The share price rose to $18.44 (+15.25%) at the... |
| 13.02.2023 | Andera Partners Portfolio Company Mineralys Therapeutics Successfully Completes Upsized $192 Million Nasdaq IPO | Andera has co-led the company’s $118 million Series B financing in June 2022 and re-invested into the oversubscribed IPO financing. |
| 10.02.2023 | Mineralys IPO Lands $192M for Blood Pressure Trials and Chance to Challenge AstraZeneca | Mineralys Therapeutics’ hypertension drug candidate could offer a new treatment option for patients who don’t adequately respond to currently available blood pressure medicines. The once-daily pill is nearing a pivotal test, and Mineralys h... |
| 09.06.2022 | Mineralys Therapeutics Closes $118 Million Oversubscribed Series B Financing to Advance the Development of Novel. Ysios participated. | 09/06/2022 Press release MINERALYS THERAPEUTICS CLOSES $118 MILLION OVERSUBSCRIBED SERIES B FINANCING TO ADVANCE THE DEVELOPMENT OF NOVEL. YSIOS CAPITAL PARTICIPATED. Mineralys Therapeutics Closes $118 Million Oversubscribed Series B Fin... |
| 09.06.2022 | Ysios Capital participa en la ronda de financiación de $118 millones en Mineralys Therapeutics | 09/06/2022 Nota de prensa YSIOS CAPITAL PARTICIPA EN LA RONDA DE FINANCIACIÓN DE $118 MILLONES EN MINERALYS THERAPEUTICS. La entidad de capital riesgo (venture capital) Ysios Capital participa en la ronda de financiación de 118 millones ... |
Show more